Overcoming Vaccine Hesitancy in Patients.

The FDA has approved Arexvy, a vaccine against respiratory syncytial virus (RSV) for adults aged 60 years or older. RSV infection led to more than 100,000 hospitalizations and 7700 deaths in older adults in the United States in 2019. Arexvy reduced severe RSV disease by 94% and RSV-related acute respiratory infections by 71%. However, patient hesitancy may be a challenge in incorporating this new vaccine into practice. It's important for healthcare providers to educate colleagues, staff, and patients about preventing serious illness caused by RSV.